Volume 7, Issue 7 February 2014
In the treatment of metastatic colorectal cancer, inferior overall survival, progression-free survival, and objective response rates have been shown in people with RAS mutations (at exons 2, 3, and 4 of KRAS and NRAS) who received cetuximab in combination with FOLFOX4 (oxaliplatin-containing) chemotherapy versus FOLFOX4 alone. Cetuximab is now indicated for the treatment of people with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in combination with irinotecan or oxaliplatin based chemotherapy or as a single agent.
A review of the latest evidence on the risk of thromboembolism in association with combined hormonal contraceptives (CHCs) has concluded that:
- the risk of blood clots with all low-dose CHCs is small
- there is good evidence that the risk of venous thromboembolism (VTE) may vary between products, depending on the progestogen
- CHCs that contain levonorgestrel, norethisterone, or norgestimate have the lowest risk of VTE
- the benefits of any CHC far outweigh the risk of serious side effects
- prescribers and women should be aware of the major risk factors for thromboembolism, and of the key signs and symptoms